168 related articles for article (PubMed ID: 25989054)
1. Investigating detrusor muscle concentrations of oxybutynin after intravesical delivery in an ex vivo porcine model.
Williams NA; Lee KM; Allender CJ; Bowen JL; Gumbleton M; Harrah T; Raja A; Joshi HB
J Pharm Sci; 2015 Jul; 104(7):2233-40. PubMed ID: 25989054
[TBL] [Abstract][Full Text] [Related]
2. An ex vivo investigation into the transurothelial permeability and bladder wall distribution of the nonsteroidal anti-inflammatory ketorolac.
Williams NA; Bowen JL; Al-Jayyoussi G; Gumbleton M; Allender CJ; Li J; Harrah T; Raja A; Joshi HB
Mol Pharm; 2014 Mar; 11(3):673-82. PubMed ID: 24460452
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
4. Muscarinic Receptor Binding in Rat Bladder Urothelium and Detrusor Muscle by Intravesical Solifenacin.
Ito Y; Kashiwabara M; Yoshida A; Hikiyama E; Onoue S; Yamada S
Biol Pharm Bull; 2016; 39(7):1167-71. PubMed ID: 27374291
[TBL] [Abstract][Full Text] [Related]
5. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity.
Van Meel TD; De Wachter S; Wyndaele JJ
Neurourol Urodyn; 2010 Mar; 29(3):391-4. PubMed ID: 19787712
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.
Oki T; Kimura R; Saito M; Miyagawa I; Yamada S
J Urol; 2004 Nov; 172(5 Pt 1):2059-64. PubMed ID: 15540789
[TBL] [Abstract][Full Text] [Related]
8. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
9. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents.
De Wachter S; Wyndaele JJ
J Urol; 2003 May; 169(5):1892-5. PubMed ID: 12686868
[TBL] [Abstract][Full Text] [Related]
10. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
Di Stasi SM; Giannantoni A; Navarra P; Capelli G; Storti L; Porena M; Stephen RL
J Urol; 2001 Dec; 166(6):2232-6. PubMed ID: 11696741
[TBL] [Abstract][Full Text] [Related]
11. Antimuscarinic actions on bladder urothelium and lamina propria contractions are similar to those observed in detrusor smooth muscle preparations.
Veer V; Chess-Williams R; Moro C
Neurourol Urodyn; 2023 Jun; 42(5):1080-1087. PubMed ID: 36975140
[TBL] [Abstract][Full Text] [Related]
12. Protective action of intravesical oxybutynin on bladder ultrastructure in rabbits with detrusor overactivity.
Yamamoto H; Kawano PR; Balasteghin KT; Padovani CR; Amaro JL
Int Urogynecol J Pelvic Floor Dysfunct; 2009 Feb; 20(2):229-34. PubMed ID: 18953475
[TBL] [Abstract][Full Text] [Related]
13. A new model of detrusor overactivity in conscious rats induced by retinyl acetate instillation.
Wróbel A; Łańcut M; Rechberger T
J Pharmacol Toxicol Methods; 2015; 74():7-16. PubMed ID: 25957030
[TBL] [Abstract][Full Text] [Related]
14. Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.
Moon HS; Lee JW; Park SY; Son YW; Kim YT
Urology; 2010 Aug; 76(2):509.e8-12. PubMed ID: 20546876
[TBL] [Abstract][Full Text] [Related]
15. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
Di Stasi SM; Giannantoni A; Vespasiani G; Navarra P; Capelli G; Massoud R; Stephen RL
J Urol; 2001 Feb; 165(2):491-8. PubMed ID: 11176403
[TBL] [Abstract][Full Text] [Related]
16. Muscarinic receptors in the bladder: from basic research to therapeutics.
Hegde SS
Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186
[TBL] [Abstract][Full Text] [Related]
17. Antimuscarinics and overactive bladder: other mechanism of action.
Yamaguchi O
Neurourol Urodyn; 2010; 29(1):112-5. PubMed ID: 19693952
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
[TBL] [Abstract][Full Text] [Related]
19. Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips--a pharmacological study towards a new treatment option of overactive bladder.
Schuler V; Suter K; Fürer K; Eberli D; Horst M; Betschart C; Brenneisen R; Hamburger M; Mennet M; Schnelle M; Simões-Wüst AP; von Mandach U
Phytomedicine; 2012 Jul; 19(10):947-51. PubMed ID: 22824522
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
